MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Topic
Lung Cancer Treatments and Mutations
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

2,464 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
2,464 works in the cohort · of 4,299,418page 23 of 50

Labels cover 16 of 2,464 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 2,464 of 2,464 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affaboutunlabeled
Hypertension (HTN) in National Cancer Institute of Canada Clinical Trials Group study BR.24: A randomized, double-blind phase II trial of carboplatin (C) and paclitaxel (P) with either daily oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo, in patients with advanced non-small cell lung cancer
Robert Goodwin, Lesley Seymour, Keyue Ding, L. Gauthier, Aurélie Le Maître, Eliot Frymire +4 more
2009· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
7
citations
afffundno abstractunlabeled
CANTRK
Tracy Stockley, Bernard Lo, Adrian Box, Andrea Corredor, John F. DeCoteau, Patrice Desmeules +19 more
2022· article· en· Journal of Molecular Diagnostics· Medicine
machine prediction:candidate · noneconsensus · none
7
citations
affunlabeled
Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1inhibitors (IO): Primary results from the phase 3 EVOKE-01 study.
Luis Paz‐Ares, Óscar Juan, Giannis Mountzios, Enriqueta Felip, Niels Reinmuth, Filippo de Marinis +12 more
2024· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
7
citations
affno abstractunlabeled
Rediscovering immunohistochemistry in lung cancer
Anna La Salvia, May‐Lucie Meyer, Fred R. Hirsch, Keith M. Kerr, Lorenza Landi, Ming‐Sound Tsao +1 more
2024· review· en· Critical Reviews in Oncology/Hematology· Medicine
machine prediction:candidate · noneconsensus · none
6
citations
affunlabeled
Lung Cancer and Cardiovascular Disease
Malak El-Rayes, Inbar Nardi Agmon, Christopher Yu, Nichanan Osataphan, Helena A. Yu, Andrew Hope +4 more
2025· review· fi· JACC CardioOncology· Medicine
machine prediction:candidate · noneconsensus · none
6
citations

How this was built: Screen · Findings · About